Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2022-09-29 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2022-09-29 English
Annual MD&A - English.pdf
Regulatory Filings
2022-09-29 English
Audited annual financial statements – English.pdf
Regulatory Filings
2022-09-29 English
News release - English.pdf
Delisting Announcement Classification · 100% confidence The document is a short announcement regarding the Toronto Stock Exchange's decision to extend the delisting review period for Aleafia Health until November 29, 2022. It does not contain financial data, detailed reports, or other substantive content beyond the delisting review update. The key phrase 'TSX Decision to Extend Delisting Review Period' and the nature of the content clearly indicate this is a Delisting Announcement. The document length is only 1039 characters, consistent with a brief announcement rather than a full report.
2022-09-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the presentation of clinical study data at a medical congress. It details the Phase 1/2 clinical study results of ketamine for Parkinson's disease, including efficacy and safety data, and mentions plans for a Phase 3 study and FDA regulatory pathway. There are no financial statements, regulatory filings, or formal reports such as annual or interim reports. The document is primarily an announcement of clinical trial results and future plans, not a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation for investors or a management discussion. The closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement or press release that does not fit other categories.
2022-09-16 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a confirmation notice regarding the record and meeting dates for an upcoming Annual General Meeting (AGM) of security holders. It includes details such as the meeting date, record date for voting, and other procedural information related to the AGM. The document does not contain the AGM materials or presentations themselves, nor does it include financial data or results. It is essentially an announcement related to the AGM logistics. Given the short length (1634 characters) and the nature of the content, this fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related notices about the AGM.
2022-09-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.